> Print and Download Article

What happens over time when glucagon-like peptide-1 (GLP-1) receptors in the brain are stimulated constantly instead of intermittently, the way the body naturally intended?

What happens when the body starts adapting to long-term stimulation from GLP-1 drugs that affect hunger, appetite, and metabolism?

And what happens when rapid weight loss also includes reduced preservation of skeletal muscle, one of the most important tissues for healthy aging, strength, mobility, metabolism, and long-term survival?

These are some of the biggest unanswered questions in obesity, metabolism, and longevity science today.

GLP-1 drugs like Ozempic, Wegovy, and Zepbound are changing the world of weight loss and diabetes care. Many people are losing weight quickly, lowering blood sugar, and improving health markers.[1] Some researchers even believe these drugs may help people live longer.[2]

But there is another side of the conversation that deserves more attention.

The Body Adapts to Repeated Stimulation

One of the most important rules in physiology is this:

The body adapts.

This happens throughout the body every day. Over time, repeated stimulation can lead to:

• • receptor desensitization (when receptors stop responding as strongly over time)
  • downregulation (when the body reduces the number of receptors available)
  • altered hormone signaling (when hormones no longer communicate normally with cells)
  • reduced natural hormone production (when the body begins making less of its own hormones)
  • compensatory feedback loops (when the body tries to adapt or compensate for long-term stimulation)[3]

We already see this with:

• • insulin resistance
  • leptin resistance
  • dopamine tolerance
  • beta-adrenergic receptor downregulation
  • altered thyroid signaling

This is normal biology.

That raises an important question:

Why would incretin pathways be immune to adaptation?

What Are Incretins?

Incretins are hormones released in the gut after eating. The two main incretin hormones are:

• • glucagon-like peptide-1 (GLP-1)
  • glucose-dependent insulinotropic polypeptide (GIP)

These hormones help:

• • increase insulin release
  • slow stomach emptying
  • reduce appetite
  • help regulate blood sugar[4]

Under normal physiology, GLP-1 is released temporarily after eating and then naturally declines.

GLP-1 receptor agonist drugs are different.

These medications can stimulate GLP-1 pathways continuously while the drug remains active in the body, including between meals and even when a person is not eating.[4]

This distinction is important.

The concern is not whether these drugs work. Clearly, they do.

The bigger question is what happens over time when nutrient-sensing pathways that evolved to function intermittently are stimulated continuously for years.

Think of nutrient-sensing and signaling pathways as the body’s internal communication and traffic-control system.

Every time you eat, your body sends messages between the brain, gut, pancreas, liver, muscles, and fat cells. These messages help decide:

• • whether you feel hungry or full
  • whether food should be burned for energy or stored as fat
  • how much insulin should be released
  • whether the body should focus on growth, storage, repair, or cleanup

Normally, these signals rise and fall naturally throughout the day, similar to traffic lights turning on and off when needed.

The concern I have, and that some researchers now share, is this:

What happens when certain pathways are constantly stimulated for long periods of time, almost like leaving a traffic light stuck on green all day long?

Over time, the body may begin to adapt to the nonstop signaling, which could affect metabolism, hormone balance, muscle preservation, and healthy aging.

It is also important to understand that eating naturally activates multiple signaling pathways in the body simultaneously, not just GLP-1. Other hormones and nutrient-sensing signals, including glucagon-like peptide-2 (GLP-2), GIP, insulin, and other gut hormones, work together in a coordinated, balanced way after eating.[5]

This is one reason some researchers are asking what may happen when a pathway is pharmacologically chronically amplified for years, outside its normal physiologic rhythm.

Chronic Stimulation and Aging

Many aging researchers now focus on pathways connected to:

• • insulin
  • mechanistic target of rapamycin (mTOR)
  • AMP-activated protein kinase (AMPK)
  • autophagy
  • mitochondrial function

These pathways help control:

• • energy production
  • repair
  • metabolism
  • inflammation
  • cellular aging itself[6]

One pathway that receives a lot of attention in aging science is the mechanistic target of rapamycin (mTOR).

Think of mTOR like a “growth switch” in the body.

When this switch is activated, the body focuses more on:

• • growth
  • building tissue
  • storing nutrients
  • and anabolic activity

At the same time, the body may spend less time focusing on repair and cleanup processes.

One of those important cleanup processes is called autophagy.

Autophagy is the body’s natural recycling and repair system. It helps remove damaged cells and cellular waste.[7]

Some longevity researchers believe that when growth pathways remain highly activated for long periods, the body may spend less time in repair mode and more time in a constant growth mode.[8]

This is one reason why many aging scientists focus on balance, flexibility, and periods of recovery rather than nonstop stimulation.

Insulin Is More Than a Blood Sugar Hormone

One of the biggest concerns regarding chronic incretin stimulation centers on insulin signaling.

Insulin is not simply a blood sugar hormone.

Insulin is also:

• • an anabolic hormone
  • a nutrient-sensing signal
  • a regulator of fat storage
  • a regulator of mTOR pathways
  • deeply connected to aging biology[9]

Researchers already know that insulin is one of the body’s major activators of mTOR.[8]

GLP-1 itself does not appear to stimulate mTOR as strongly or directly as insulin. However, GLP-1 drugs influence insulin signaling and nutrient-sensing pathways while the medication remains active in the body, especially after eating and during rising glucose levels, which may indirectly influence mTOR and other pathways connected to metabolism and aging.[9]

This raises another important question:

What happens when insulin-related nutrient-sensing pathways are repeatedly amplified over long periods of time?

Some researchers are now discussing whether chronic overstimulation could potentially contribute to:

• • altered metabolic signaling (when the body’s normal communication about energy, hunger, fat storage, and metabolism begins changing)
  • reduced metabolic flexibility (when the body becomes less efficient at switching between burning carbohydrates and fat for energy)
  • impaired endogenous responsiveness (when the body’s natural hormone and signaling responses may no longer function as effectively)
  • compensatory adaptations (when the body adjusts or compensates in response to long-term stimulation)
  • unintended aging tradeoffs (possible long-term consequences that may affect healthy aging in ways researchers do not yet fully understand)

The long-term answers are still unknown.

 

The Muscle Preservation Problem

One of the biggest concerns surrounding rapid weight loss is reduced preservation of skeletal muscle.

Studies on GLP-1 drugs have shown that some individuals lose meaningful amounts of lean body mass during weight loss.[10]

This concern may be especially important for adults over age 65, who are already at increased risk for age-related muscle loss, also known as sarcopenia.[11]

This matters because muscle is not just for appearance.

Muscle helps:

• • regulate blood sugar
  • support metabolism
  • improve mitochondrial health
  • protect the body during illness
  • support mobility and balance
  • improve healthy aging and survival[12]

In fact, low muscle mass is strongly linked to:

• • frailty
  • falls
  • weakness
  • loss of independence
  • higher mortality risk[13]

A person can lose weight while at the same time becoming less physically strong, less metabolically flexible, and less able to handle stress, illness, or aging.

This is why preserving skeletal muscle during weight loss may be just as important as reducing body fat itself.

Are the Benefits Coming From the Drug or From Eating Less?

Another important question is this:

Are many of the improvements coming from the medication itself, or from simply eating less food?

When people:

• • reduce calorie intake
  • lose visceral fat
  • reduce ultra-processed foods
  • lower insulin spikes
  • reduce inflammation

they often improve:

• • blood sugar
  • liver fat
  • triglycerides
  • blood pressure
  • inflammatory markers[14]

These same improvements are also seen with:

• • nutrition education
  • exercise
  • resistance training
  • healthier food quality
  • improved sleep
  • fasting
  • sustainable lifestyle changes

In my clinical experience, I have helped thousands of people improve these same markers through nutrition education, blood sugar stabilization, healthier food combinations, metabolic flexibility, and sustainable lifestyle changes using the Diet Free Life methodology.

This is one reason why long-term questions about chronic incretin overstimulation deserve more discussion.

Another Major Concern: We Still Do Not Have Decades of Long-Term Data

One of the biggest concerns surrounding GLP-1 drugs is that we still do not fully understand the long-term effects of chronic incretin stimulation, especially when these medications are used for obesity and long-term weight management.

While GLP-1 drugs have existed for nearly 20 years, their widespread use for obesity is still relatively new.[15]

Even more important, most people do not remain on these medications long term.

Real-world studies show that many people stop taking GLP-1 drugs within one to two years, and some analyses suggest that only a small minority remain on them after three years.[16]

This raises several important questions:

What happens after years of chronic stimulation is suddenly removed?

What happens to hunger signaling, appetite regulation, metabolism, and endogenous hormone responsiveness after discontinuation?

What happens to skeletal muscle preservation, metabolic flexibility, and long-term aging pathways?

And what happens when millions of people are exposed to chronic pharmacologic stimulation before decades of long-term aging data exist?

These are important concerns because physiology often involves tradeoffs.

In biology, short-term improvements do not always predict long-term outcomes.

Many of the studies showing benefits from GLP-1 drugs involve:

• • improved weight loss
  • lower blood sugar
  • reduced cardiovascular risk markers
  • reduced inflammation
  • lower liver fat

But many of these same improvements can also occur when people:

• • eat less food
  • reduce ultra-processed foods
  • lower calorie intake
  • reduce visceral fat
  • improve nutrition quality
  • improve sleep
  • increase physical activity
  • improve metabolic flexibility naturally

This is why some researchers are now asking a deeper question:

Are the long-term benefits coming from the drug itself, or from the physiologic effects of eating less and losing weight?

At the same time, other important concerns remain largely unanswered, including:

• • altered hormone signaling (when hormones may no longer send, receive, or respond to messages the same way they once did)
  • receptor adaptation (when receptors begin adjusting to constant stimulation and may become less sensitive or responsive over time)
  • reduced metabolic flexibility (when the body becomes less efficient at switching between burning fat and carbohydrates for energy, depending on the body’s needs)
  • reduced preservation of skeletal muscle (when the body loses or struggles to maintain healthy muscle tissue that supports strength, metabolism, mobility, blood sugar control, and healthy aging)
  • and unintended aging consequences (possible long-term effects that may negatively influence the body’s natural repair, recovery, resilience, and healthy aging processes)

This does not prove long-term harm.

But the gaps in long-term data should encourage caution, especially when millions of people may remain on these medications for years or even decades before the full physiologic consequences are understood.

The Concern About Metabolic Adaptation

The human body constantly adapts.

Researchers are now discussing whether chronic stimulation of incretin pathways could eventually contribute to:

• • reduced endogenous GLP-1 responsiveness
  • altered hunger signaling
  • dependence on external stimulation
  • rebound weight gain after stopping medication
  • reduced metabolic flexibility
  • changes in energy expenditure[17]

This does not mean these outcomes are guaranteed.

It means the long-term science is still evolving.

That is important because many people may remain on these medications for years or even decades.

Weight Loss Is Not Always the Same as Healthy Aging

This may be the most important point of all.

Lower body weight does not automatically mean better long-term health.

Healthy aging involves:

• • preserving muscle
  • maintaining strength
  • improving metabolic flexibility
  • reducing inflammation
  • supporting mitochondrial health
  • maintaining healthy hormone signaling
  • preserving physiologic resilience

The goal should not simply be eating less.

The goal should be to help the body function better.

Final Thoughts

GLP-1 drugs are changing the field of obesity and metabolic medicine. There is no question that they can help many people lose weight and improve certain health markers.

But there are still important unanswered questions.

Could chronic pharmacologic overstimulation of nutrient-sensing pathways eventually contribute to:

• • altered hormone signaling
  • receptor adaptation
  • reduced metabolic flexibility
  • reduced preservation of skeletal muscle
  • and unintended aging consequences?

Science does not yet have all the answers.

But history has shown that when we manipulate human physiology before fully understanding the long-term consequences, we often discover the tradeoffs later.

The future of healthy aging may not come from overriding the body’s signals, but from improving metabolic flexibility, preserving skeletal muscle, reducing inflammation, supporting mitochondrial health, and helping the body function better naturally.

Want Help Improving Your Health Naturally?

If you are currently taking a GLP-1 drug, considering one, transitioning off one, or simply want to improve your metabolism, body composition, inflammation, blood sugar, or overall health naturally, I would be happy to help.

I provide personalized nutrition coaching and education using the Diet Free Life methodology, which focuses on:

• • blood sugar stabilization
  • healthier food combinations
  • metabolic flexibility
  • muscle preservation
  • reducing inflammation
  • and sustainable long-term lifestyle changes

To schedule a free consultation, visit: Schedule a Free Consultation

You can also email me directly at: robert@dietfreelife.com.

References

1. 1. Singh, G., Krauthamer, M., & Bjalme-Evans, M. (2022). Wegovy (semaglutide): A new weight loss drug for chronic weight management. Journal of Investigative Medicine, 70(1), 5–13.
   2. Kulkarni, A. S., et al. (2024). GLP-1 receptor agonists and healthy aging: Emerging evidence and unanswered questions. Nature Aging, 4(2), 145–156.
   3. Fadini, G. P., & Avogaro, A. (2011). Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1. Vascular Pharmacology, 55(1-3), 10–16.
   4. Holst, J. J. (2007). The physiology of glucagon-like peptide 1. Physiological Reviews, 87(4), 1409–1439.
   5. Drucker, D. J. (2002). Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology, 122(2), 531–544.
   6. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013). The hallmarks of aging. Cell, 153(6), 1194–1217.
   7. Mizushima, N., & Komatsu, M. (2011). Autophagy: Renovation of cells and tissues. Cell, 147(4), 728–741.
   8. Saxton, R. A., & Sabatini, D. M. (2017). mTOR signaling in growth, metabolism, and disease. Cell, 168(6), 960–976.
   9. Barzilai, N., Huffman, D. M., Muzumdar, R. H., & Bartke, A. (2012). The critical role of metabolic pathways in aging. Diabetes, 61(6), 1315–1322.
   10. Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216.
   11. Cruz-Jentoft, A. J., et al. (2019). Sarcopenia: Revised European consensus on definition and diagnosis. Age and Ageing, 48(1), 16–31.
   12. Wolfe, R. R. (2006). The underappreciated role of muscle in health and disease. The American Journal of Clinical Nutrition, 84(3), 475–482.
   13. Bhasin, S., et al. (2023). Muscle preservation and obesity treatment in older adults. Journal of the American Geriatrics Society, 71(5), 1348–1359.
   14. Hall, K. D., & Guo, J. (2017). Obesity energetics: Body weight regulation and the effects of diet composition. Gastroenterology, 152(7), 1718–1727.
   15. Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 27(4), 740–756.
   16. Prime Therapeutics. (2024). Real-world persistence and adherence to GLP-1 medications for weight loss. Prime Therapeutics Research Report.
   17. Müller, T. D., Finan, B., Bloom, S. R., D’Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130.

__________
Robert Ferguson is a California- and Florida-based single father of two daughters, clinical nutritionist, Omega Balancing Coach™, researcher, best-selling author, speaker, podcast and television host, health advisor, NAACP Image Award Nominee, creator of the Diet Free Life methodology, and Chief Nutrition Officer for iCoura Health. He also serves on the Presidential Task Force on Obesity for the National Medical Association and the Health and Product Advisory Board for Zinzino, Inc.

🗓️ Schedule a FREE consultation with Robert Ferguson about becoming a client: SCHEDULE FREE CONSULTATION

👉🏽 To order the BalanceOil+ with the BalanceTEST, > CLICK HERE

👉🏽 Watch a free online presentation on the BalanceOil+ and the BalanceTEST: WATCH NOW.